The halal food industry is on a significant trajectory and this trend is expected to continue escalating imminently. However, the halal and thayyib food supply chain issues involving manufacturing, distribution and consumption have not been solved and are causing concern among the Muslim community in Brunei Darussalam. One issue includes the sugar decolorising process by using bone char and/or activated carbon, which include animal bones as a raw material. Ethanol is another issue that is present in conventional and fermented products like beverages, sauces and additives. Brunei has a high importation rate of food products from Muslim-minority countries, resulting in numerous products with unknown halal status, as well as produces local fermented food products widely sold in the market. The current study provides a mini review of the involvement of animal bones and ethanol in food-related products. Moreover, the study presents a compilation of related fatwas on animal bones and ethanol issued by Brunei and neighbouring countries namely Malaysia, Indonesia and Singapore to investigate the halal status of the implicated products. Brunei imposes a strict stance on these issues, whereby any involvement of pigs, dogs and permissible animals that are not slaughtered based on Shariah principles will deem the food-related products haram, as well as industrial ethanol is considered haram so no trace of such type is allowed (0.00%) in food and beverages. In conclusion, halalan thayyiban issues may be overcome in further studies by involving a collaboration of authorities in addressing scientific findings supported with Shariah principles.
Background: Breast cancer is the most frequent malignancy affecting women worldwide. The majority of breast cancer occurs sporadically, with only 5-10% being caused by inheritance of susceptibility genes. In Brunei Darussalam, breast cancer is the leading cause of cancer in women. The prevalence and clinical relevance of breast cancer susceptibility genes in Brunei breast cancer patients is unknown. We investigated the prevalence and clinical relevance of germline TP53 and PALB2 genes, recognised to confer a high and moderate risk respectively, in the development of breast cancer in an unselected cohort of Brunei breast cancer patients. Methods: Genomic DNA was extracted from peripheral blood samples of 54 unselected Brunei breast cancer patients. The DNA samples were sequenced for germline BRCA1, BRCA2, TP53, and PALB2 variants using targeted panel sequencing on a Hi-Plex NGS platform. Identified variants were analysed for their pathogenicity classification based on clinical/population/mutation databases, in-silico data, and available functional data analysis. Chi-square test was used to determine the association between TP53 codon 72 and response to chemotherapy in Brunei breast cancer patients. Results: We identified two TP53 and five PALB2 missense variants in our study population. Five of the identified variants were classified as variants of uncertain significance (one in TP53 and four in PALB2) giving a prevalence of TP53 and PALB2 variant of uncertain significance carriers at 1.9% and 9.3%, respectively. No pathogenic TP53 and PALB2 mutation was identified in this study suggesting the rarity of these genes in breast cancer.TP53 codon 72 had no association with Brunei breast cancer patients’ response to chemotherapy supporting the benign characteristic of the variant P72R. Conclusions: Our current findings suggest that the contribution of germline TP53 and PALB2 genes in unselected Brunei breast cancer patients is rare, and a larger number of participants will be required to confirm this finding.
This is the first genetic study of its kind in Brunei Darussalam. BRCA1 and BRCA2 genes are the most well-known and well described predictors of hereditary breast cancer due to their clinical importance. This study aimed to identify the prevalence and mutation spectrum of the BRCA1 and BRCA2 germline mutations among 120 unselected series of Brunei breast cancer patients. We screened the entire coding region of BRCA1 and BRCA2 gene using Sanger sequencing and next-generation sequencing methods, and identified three pathogenic and one likely pathogenic mutations in the BRCA2 gene. Of the 120 patients, 6 (5%) were BRCA2 carriers which confirm that BRCA2 carriers are more common in the Asian population compared to the Caucasian population. One BRCA2 mutation observed only in the Chinese ethnicity of the Brunei breast cancer population contributes to the probability of the mutation being a founder effect in the Southern Chinese population. Brunei BRCA2 carriers were more likely to have a positive family history of breast and/or ovarian cancers and have more than one family members in the first-degree relatives diagnosed with breast cancer.
This is the first genetic study of its kind in Brunei Darussalam. BRCA1 and BRCA2 genes are the most well-known and well described predictors of hereditary breast cancer due to their clinical importance. This study aimed to identify the prevalence and mutation spectrum of the BRCA1 and BRCA2 germline mutations among 120 unselected series of Brunei breast cancer patients. We screened the entire coding region of BRCA1 and BRCA2 gene using Sanger sequencing and next-generation sequencing methods and identified three pathogenic and one likely pathogenic mutations in the BRCA2 gene. Of the 120 patients, 6 (5%) were BRCA2 carriers which confirm that BRCA2 carriers are more common in the Asian population compared to the Caucasian population. One BRCA2 mutation observed only in the Chinese ethnicity of the Brunei breast cancer population suggest a probability of the mutation being a founder effect in the Southern Chinese population. Brunei BRCA2 carriers were more likely to have a positive family history of breast and/or ovarian cancers and have more than one family members in the first-degree relatives diagnosed with breast cancer.
Spleen tyrosine kinase (Syk) gene encodes a non-receptor type tyrosine kinase which is widely expressed in many cell types and is a known tumor suppressor for human breast carcinomas. Studies have reported that mutations in Syk gene are associated with cell invasion and an increased risk of cancer development. In this study the mutational status of the entire coding region of Syk was analysed in breast cancer patients in Brunei Darussalam. By using Sanger sequencing method, the germ-line mutations of Syk gene in breast cancer patients were identified. Analysis of sequencing result revealed seven previously unreported single nucleotide alterations in the coding region of the Syk gene of which five mutations were observed to be silent mutations. Two silent mutations, c.267C > Y and c.384G > R, were observed in exon 2, while one mutation, c.1320C > Y, was observed in sample exon 9. The remaining 2 silent mutations were c.1752T > Y and c.1800T > Y, observed on exon 11. Two missense variations, namely c.1807G > R and c.1834A > M, were identified in exon 11 of the Syk gene which encodes part of kinase domain of the Syk gene. All of these mutations are reported for the first time in this study. Additionally, substitution and deletion mutations were also detected in the non-coding region of the Syk gene. The importance of these mutations in breast cancer pathogenesis at this stage is not clear and requires further work.